Cellprep [Biotecnología Celular]

1- Steinman R., Cohn Z. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, Quantitation , tissue distribuiton. J. Exp. Med. 1973; 137: 1142-62.

2- Lanzavecchia A. Mechanisms of antigen uptake presentation. Curr. Opin. Immunol. 1996; 8: 348-54.

3- Fearnley D.B., Whyte L.F., Carnoutsos S.A., et al. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999; 93:728-736.

4- Jiang W., Swiggard W.J., Heufler C., et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151-155.

5- Bancherau J., Schuler-Thurner B., Palucka A.K., et al. Dendritic cells as vectors for therapy. Cell 2001; 106: 271-274

6- Grabbe S., Kämpgen E., Schuler G., et al. Dendritic cells: multi-lineal and multifuntional. Trends Immunology Today 2000; 21 (9): 431-433.

7- Tan M.C., Mommaas A.M., Drijfhout J.W., et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol. 1997; 27: 2426-2435.

8- Inaba K., Turley S., Yamaide F., et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 1998; 188: 2163-2173.

9- Albert M.L., Sauter B and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.

10- Svensson M., Stockinger B and Wick M.J. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J. Immunol. 1997; 158: 4229-4236.

11- Brossart P. and Bevan M.J. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997; 90: 1594-1599.

12- Shortman K., Caux C. Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 1997; 15: 409-19.

13- Lanzavecchia A. and Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263-266.

14- Delves P. and Roitt I.. The immunogy System. New Eng J of Med 2000; 343 (2): 108-117.

15- Fong, L.; Hou, Y.; Rivas, A. et al. In vivo expansion of dendritic cells with Flt3L for human tumor immunotherapy. Blood 1999; 94 (10) Suppl. 1: 378a. Abst. # 1683.

16- Valone F., Small E., MacKenzie M., et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. The cancer Journal 2001; 7 (2): s53-s61.

17- Caux, C.; Dezutter-Dambuyant, C.; Schmitt D., Bancherreau, J. GM-CSF and TNF-a cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-61.

18- Strunk, D.; Rappersberger, K.; Egger, C.; Strobl, H.; Krömer, E.; Elbe, A. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996; 87: 1292-302.

19- Peters, J.; Xu, H.; Ruppert, J.; Ostermeier,D.; Friedrichs, D.; Gieseler, R. Signals required for differenting dendritic cells from human monocytes in vitro. Advances in Exp. Med. and Biol. 1993; 329: 275-80.

20- Zhou, L.; Tedder, T. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA 1996; 93: 2588-92.

21-Caux C., Massacrier C., Vanbervliet B., et al. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 1994; 180: 1263-1272.

22-Paschen A., Dittmar K.E., Grenningloh R., et al. Human dendritic cells infected by Literia monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eu. J. Immunol. 2000; 30: 3447-3456.

23-Kato T., Yamane H. and Nariuchi H. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell Immunol. 1997; 181: 59-67.

24-Hartmann G., Weiner G.J. and Krieg A.M. CpG DNA: a potent signal for growth, activation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 1999; 96: 9305-9310.

25-Singh-Jasuja H., Scherer H.U., Hilf N. et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 2000; 30: 2211-2215.

26-Jonuleit H., Kuhn U., Muller G., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 1997b; 27: 3135-3142.

27- Herbst B., Kohler G., Mackensen A., Veelken H., Lindemann A. GM-CSF promotes differentiation of a precursor cell of monocytes and Langerhans-type dendritic cells from CD34+ haematopoietic progenitor cells. Brit. J. Haematol. 1998; 101: 231-41.

28-Butterfield L.H., Jilani S.M., Chakraborty N.G., et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 1998; 161: 5607-5613.

29-Zhong L., Granelli-Piperno A., Choi Y., et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 1999; 29: 964-972.

30-Chakraborty, N.G., Sporn J.J.R., Tortora A.F., et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother. 1998; 47: 58-64.

31-Kugler A., Stuhler G., Walden P., et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med. 2000; 6: 332-336.

32-Grabbe S., Vbeissert S., Schwarzt T., et al. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?. Immunology Today 1995; 16: 117-121.

33-PeaceD., Chen W., Nelson H. T cell recognition of transforming protein encoded by mutated ras proto-oncogenes. Immunol. 1991; 146: 2059-65.

34-Fisk B., Blevis T., Wharton J. Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med 1995; 181: 2109-2065.

35-Peoples G., Goedegebuure P., Smith R. Breast and ovarian cancer-specific cytotoxic T lymphocites recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA. 1995; 92: 432-6.

36-Kawakami Y., Eliyahu S., Sakaguch K. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-restricted tumor infiltrating lymphocytes. J. Exp. Med. 1994; 180: 347- 52.

37-Castelli C., Sotrkus W., Maeurer M. Mass spectometric identification of a natural-processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med. 1995; 181: 363-8.

38-Bakker A., Schreurs N., de Boer A. Melanocyte lineage-specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J. Exp Med. 1994; 179: 1005-9.
39-DeLeo AB. p53-based immunotherapy of cancer. Crit. Rev. Inmunol. 1998; 18: 29-35.

40-Hsu F., Benike C., Fagnoni F. et al. Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. Nature Med. 1996; 2: 52-8.

41-Kotera Y, Fontenot J., Pecher G., Metzgar R., Finn O. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54: 2856-60.

42-Finn O., Jerome K., Henderson R. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 1995; 145: 61-89.

43-Traversari C., Van der Bruggen P., Luescher Y., Lurquin C., Chomez P., Van Pel A. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992; 176: 1453-8.

44-Boel P., Wildmann C., Sensi M. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167-75.

45-Albert M., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.

46-Nestle F., Alijagic S., Gilliet M. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 1998; 4: 328-332.

47-Nieda, M., Nicol, A., Kikuchi, A., et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998; 91 (3): 977-83.

48-Osman, Y., Takahashi, M., Zheng, Z., et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J. Exp. Clin. Cancer Res. 1999; 18 (4): 485-92.

49-Clark, R., Dodi I, Hill, S. et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001; 98(10):2887-2893.

50-Miwa, H., Beran, M., Saunders, G. Expression of the Wilm's tumor gene (wt1) in human leukemias. Leukemia. 1992; 6: 405- 9.

51-Menssen, H., Renkl, H., Rodeck, U. et al. Presence of Wilm's tumor gene (wt1) transcripts and WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995; 9: 1060-7.

52-Ohminami, H., Yasukawa, M., Fujita, S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000; 95 (1): 286-93.

53-Choudhury,A., Liang, J., Thomas,E., et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93 (3): 780-6.

54-Thurner B., Haendle Y., Roder C., et al. Vaccination with mage-3A1 peptide-pulsec mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999; 190: 1669-1678.

55-Murphy GP, Tjoa BA, Simmons SJ et al. Infusion of dendritic cells pulsed with HLA-A2-specific-prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 1999; 38:73-8

56-Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000; 6:2175-82.

57-Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000; 18: 3894-3903.

58-Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood. 1999; 93:2411-19.

59-Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83:215-22.

60-Holtl L, Rieser C, Papesh C, et al. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer [letter]. Lancet. 1998;352:1358.

61- Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999; 161:777-82.

62-Mackensen A., Herbst, B., Chen, J. et al. Induction of antigen-specific immune responses in melanoma patients after vaccination with peptide-pulsed dendritic cells. Blood 1999; 94 (10) Suppl. 1: 216a. Abst. # 950.

63-Faid, L., Toungouz, M., Libin, M., et al. In patients with Mage-1, -3 positive tumors, the injection of autologous dendritic cells pulsed with Mage-1, -3 peptides induces a transient specific induction of blood anti-Mage-1, -3 T cells that is not improved by keyhole-Limpet hemocyanin used as non-specific help. Proceedings of ASCO 2000: 454a. Abst. # 1779.

64-Cajal, R., Mayordomo, J., Yubero, A. et al. Immunological and clinical effects of immunotherapy with dendritic cells pulsed with tumor lysates in patients with advanced cancer. A pilot trial. Proceedings of ASCO 2000: 454a. Abst. # 1780.

65-Tjoa, B., Simmons, S., Bowes, V., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36 (1): 39-44.

66-Märten A., Renoth S., Heinicke T. et al. Allogeneic dendritic cells fused tumor cells: preclinical results and outcome of a first clinical phase I/II trial in patients with metastatic renal cell carcinoma. Blood 2001; 98: 406a. Abst. # 1703.

67-Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res. 2001;7(1):23-31.

68-Brossart, P., Stuhler, G., Reichardt, V. et al. Vaccination therapy of patients with metastatic breast and ovarian carcinoma using peptide pulsed debdritic cells. Blood 1999; 94 (10) Suppl. 1: 216a. Abst. # 949.

69-Avigan D., Gong J., Uhl L.et al. Dendritic cell tumor fusions as a novel tumor vaccine: a phase I trial for patients with metastatic breast cancer. Blood 2001; 98: 14a. Abst. # 45.

70-Liso, A., Stockerl-Goldstein, K., Aufferman, S., Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Blood 1999; 94 (10) Suppl. 1: 715a. Abst. # 3156.

71-Titzer, S., Christensen, O., Manzke, O. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 2000; 108 (4): 805-16.

72-Yi Q., Desikan R., Barlogie B. et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Blood 2001; 98: 374a. Abst. # 1576.

73-Timmerman, J., Davis, T., Hsu, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immunological responses in 26 patients. Blood 1999; 94 (10) Suppl. 1: 385a. Abst. # 1712.

74-Bedandi M., Gocke C.D., Kobrin C.B. et al. Complete molecular remissions induced by patient-specidic vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 1999; 5: 1171-7.

75-Westermann J., Kopp J., Körner I. et al. Dendritic cells as vaccine in BCR-ABL-positive chronic myelogenous leukemia - A phase I study. Blood 2001; 98: 350a. Abst. # 1477.

76-Keever-Taylor, C., Margolis, D., Sandford, G., Miller, K., Fisher, B., Burns, W. Generation of cytomegalovirus-specific cytolitic T cell lines and clones using pp65 transfected dendritic cells. Blood 1999; 94 (10) Suppl. 1: 152a. Abst. # 667.

77-Glinz, S., Linari, S., Caporale, R., Bosi, A., Rossi Ferrini, P. In vitro generation of CMV-specific cytotoxic T lymphocites using CMV-peptide pulsed dendritic cells. Bone Marrow Transpl. 2000; 25, Supplement 1: S121, Abst. P347.

78-Diamond, D.; York, J.; Sun, J.; Wright, C.; Forman, S. Development of candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997; 90 (5): 1751-67.

79-Subklewe, M., Chahroudi, A., Schmaljohn, A., Kurilla, M., Bhardwaj, N., Steinman, R. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. Blood 1999; 94 (4): 1372- 1381.

80-Takahashi, H., Nakagawa, Y., Yokomuro, K., Berzofsky, J. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 1993; 5 (8): 849-857.

81-Kundu, S., Engleman, E., Benike, C., et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 1998; 14 (7): 551- 60.

82-Geijtenbeek, T., Torensma, R., van Vliet, S., et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100: 575- 85.

83-Teunis, B., Geijtenbeek, T., Kwon, D. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100: 587- 97.

84-Steinman, R. DC-SIGN: a guide to some mysteries of dendritic cells. Cell 2000; 100: 491-4.

85-Morse M., Coleman E., Akabani G., et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Research 1999; 59: 56-58.

86-Thomas R., Chambers M., Boytar R., et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 1999; 9: 474-481.

87-Banchereau J., Steinman, R. Dendritic cells and the control of immunity. Nature 1998; 392: 245- 52.